1407429-97-3

Usage

Uses

Used in Pharmaceutical Industry:
4-iodo-1-(2-methoxyethyl)-1H-pyrazole is used as a key intermediate in the synthesis of naphthyridine compounds. These compounds act as inhibitors of Hematopoietic progenitor kinase 1 (HPK1), which is a protein kinase involved in the regulation of immune cell activation and proliferation. Inhibition of HPK1 has been shown to have potential therapeutic benefits in the treatment of various types of cancer.
The application of 4-iodo-1-(2-methoxyethyl)-1H-pyrazole in the pharmaceutical industry is primarily due to its role in the development of novel cancer therapeutics. By targeting HPK1, these naphthyridine compounds may offer a new approach to cancer treatment, potentially leading to improved patient outcomes and better management of the disease.

Upstream product

• 3469-69-0 4-iodopyrazole 
• 627-42-9 2-chloroethyl methyl ether 
• 6482-24-2 2-Bromoethyl methyl ether 
• 304693-68-3 1-(2-methoxyethyl)-1H-pyrazole 

Downstream Products

• 847818-71-7 1-(2-methoxyethyl)-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole 

Relevant academic research and scientific papers

Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors

Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. Here we report the discovery and optimization of 1H-pyrazolo[3,4-d]pyrimidin-4-amino as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Our optimization study gave compound 12a, which exhibited potent JAK3 inhibitory activity (IC50 of 6.2 nM) as well as excellent JAK kinase selectivity (>60-fold). In cellular assay, 12a exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation (IC50 of 9.4 μM). Further, compound 12a showed efficacy in delayed hypersensitivity assay. The data supports the further investigation of these compounds as novel JAKs inhibitors.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF

The present invention provides herein is a heteroaryl compound or a stereoisomer, a geometric isomer, a tautomer, a racemate, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, as well as a pharmaceutical composition containing the compound disclosed herein. The present invention also provides herein is use of the compound or the pharmaceutical composition thereof disclosed herein in the manufacture of a medicine for treating autoimmune diseases or proliferative diseases.

COMT INHIBITORS

The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). The compounds may be used for the treatment of Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.